2
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
178
Lung Neoplasms
56
Neoplasms
14
NSCLC
11
Brain Neoplasms
11
Neoplasm Metastasis
10
Carcinoma
9
Meningeal Carcinomatosis
6
Colorectal Neoplasms
5
Bronchial Neoplasms
5
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Lung Diseases
3
Carcinoma, Squamous Cell
3
Breast Neoplasms
3
Adenocarcinoma of Lung
3
Adenocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Prostatic Neoplasms
2
Noonan Syndrome
2
Non Small Cell Lung Cancer Metastatic
2
Interventions
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
EGFR T790M Mutation Positive NSCLC
×
osimertinib
×
Clear all
NCT02451852
2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available